Skip to main content

Table 2 Anthropometric parameters and fasting levels of the blood parameters before and after the intake of control or active FM

From: Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic subjects

Parameters

Period

W0

W4

Change from W0

P value

Anthropometric parameters

 Body weight

Control

70.5

(2.4)

70.3

(2.4)

−0.23

(0.26)

0.093

  (kg)

Active

70.7

(2.4)

70.6

(2.3)

−0.04

(0.12)

 BMI

Control

24.5

(0.5)

24.4

(0.5)

−0.09

(0.09)

0.512

  (kg/m2)

Active

24.5

(0.5)

24.5

(0.5)

−0.01

(0.04)

 Waist

Control

87.4

(1.5)

85.6

(1.3)

−1.78

(0.53)

0.461

  (cm)

Active

85.4

(1.5)

84.7

(1.4)

−0.75

(0.35)

Blood parameters

 TAG

Control

246.5

(18.9)

272.4

(26.9)

25.9

(24.9)

0.528

   (mg/dl)

Active

268.3

(31.5)

273.4

(33.5)

5.2

(14.4)

 NEFA

Control

0.382

(0.033)

0.472

(0.034)

0.090

(0.037)

0.0003

   (mEq/l)

Active

0.399

(0.031)

0.344

(0.026)

−0.056

(0.026)

 Apo B-48

Control

9.38

(1.44)

9.98

(1.31)

0.59

(0.76)

0.173

   (μg/ml)

Active

10.24

(2.06)

9.25

(1.46)

−0.98

(0.89)

 Total cholesterol

Control

215.7

(9.1)

220.5

(8.6)

4.8

(4.3)

0.797

   (mg/dl)

Active

214.1

(7.0)

217.2

(7.8)

3.1

(4.4)

 LDL cholesterol

Control

128.7

(8.3)

132.5

(7.1)

3.8

(4.0)

0.347

   (mg/dl)

Active

127.0

(7.0)

125.0

(7.3)

−2.0

(3.4)

 HDL cholesterol

Control

43.5

(2.0)

43.4

(2.1)

−0.2

(0.8)

0.504

   (mg/dl)

Active

43.6

(2.4)

42.4

(2.2)

−1.2

(1.2)

 Glucose

Control

94.5

(2.0)

94.1

(2.0)

−0.4

(1.0)

0.883

   (mg/dl)

Active

93.4

(2.6)

93.4

(2.0)

0.0

(1.9)

 Insulin

Control

9.01

(0.66)

8.60

(0.85)

−0.41

(0.46)

0.998

   (μU/ml)

Active

10.63

(2.39)

10.22

(0.95)

−0.41

(2.45)

 Amylase

Control

81.5

(8.3)

94.3

(21.1)

12.8

(14.5)

0.217

   (U/l)

Active

103.5

(21.4)

91.5

(15.3)

−12.0

(8.6)

 HbA1c

Control

5.04

(0.04)

5.01

(0.05)

−0.03

(0.03)

0.002

   (%)

Active

5.05

(0.05)

5.13

(0.05)

0.08

(0.01)

 Total protein

Control

7.05

(0.07)

7.14

(0.06)

0.09

(0.05)

0.192

   (g/dl)

Active

6.99

(0.07)

7.00

(0.07)

0.01

(0.04)

 ALP

Control

215.9

(13.0)

219.3

(13.5)

3.4

(4.6)

0.421

   (U/l)

Active

209.3

(12.3)

227.5

(20.8)

18.2

(16.2)

 AST

Control

20.8

(1.2)

20.7

(1.2)

−0.1

(0.8)

0.974

   (U/l)

Active

21.0

(1.2)

21.0

(1.1)

0.0

(0.9)

 ALT

Control

24.8

(1.8)

24.2

(2.3)

−0.6

(1.7)

0.674

   (U/l)

Active

23.2

(2.1)

23.9

(1.9)

0.7

(1.7)

 LDH

Control

159.9

(3.4)

159.3

(3.0)

−0.6

(1.8)

0.055

   (U/l)

Active

154.4

(2.9)

161.2

(4.2)

6.8

(2.6)

 γ-GTP

Control

49.2

(7.5)

52.8

(7.0)

3.7

(3.0)

0.484

   (U/l)

Active

48.3

(7.1)

61.6

(17.3)

13.4

(12.3)

 Total bilirubin

Control

0.82

(0.09)

0.81

(0.06)

−0.01

(0.06)

0.088

   (mg/dl)

Active

0.88

(0.06)

0.71

(0.06)

−0.18

(0.04)

 
  1. Abbreviations: TAG triacylglycerol, NEFA non-esterified fatty acid, Apo apolipoprotein, LDL low-density lipoprotein, HDL high-density lipoprotein, HbA1c hemoglobin A1c, ALP alkaline phosphatase, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactase dehydrogenase, γ-GTP gamma-glutamyl transpeptidase. The data are expressed as mean (SE) at each time point before (week 0, W0) and after (week 4, W4) intake of control or active FM (n = 20). A paired t test was performed to compare the changes in the response to the control and active FM.